1 active not recruiting, 1 not yet recruiting, 1 recruiting. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Iopofosine I 131: new trials by email Literature Review of Iopofosine I 131 trials Research Report on Iopofosine I 131
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer Iopofosine I 131, CLR 125 - Breast Cancer | Phase 1 | Recruiting | Cellectar Biosciences, Inc. | 60 | 2025-12-05 | 2026-10-08 |
| Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG CLR 131 - High-Grade Glioma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 50 | 2023-10-01 | 2026-10-01 |
Breast Neoplasms (1) · Glioma (1) · Triple Negative Breast Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
Cellectar Biosciences, Inc. (3)
United States (2) · Canada (1)
Jarrod Longcor (2)